In short
Clinical trials are studying Hydroxocobalamin as part of a phase 3 cancer study in people with advanced non-small cell lung cancer. The trial is comparing treatment groups to see which approach better delays disease worsening and improves survival. It focuses on adults with stage IIIB/C or stage IV nonsquamous tumors that are PD-L1 negative and KRAS p.G12C positive.
Key points
- Clinical trials investigating Hydroxocobalamin are being reported in a phase 3 study in advanced non-small cell lung cancer. The study includes people with stage IIIB/C or stage IV nonsquamous tumors that are PD-L1 negative and KRAS p.G12C positive. Researchers are comparing treatment groups and measuring progression-free survival and overall survival. The trial is authorised and plans to enroll 721 participants. The study uses blinded review of disease progression based on RECIST v1.1 rules.
Trial overview
The available trial data show one interventional study, which means researchers assign participants to study treatments rather than just observing them. This trial is a Phase 3 study in advanced lung cancer and is currently listed as authorised.
The study title describes a comparison of front-line platinum doublet therapy with sotorasib versus pembrolizumab in people with PD-L1 negative, KRAS p.G12C positive advanced or metastatic non-small cell lung cancer. Hydroxocobalamin is listed among the study interventions in the trial record.
Who can join the study
The trial is designed for people with stage IV or advanced stage IIIB/C nonsquamous non-small cell lung cancer. It also requires the tumor to be PD-L1 negative and KRAS p.G12C positive.
These details matter because they define the exact patient group the researchers want to study. In simple terms, the trial is focused on people with a specific advanced lung cancer type and a specific tumor test pattern.
Treatments being compared
The trial record lists several drugs in the intervention section, including Hydroxocobalamin, dexamethasone, sotorasib, folic acid, carboplatin, pembrolizumab, and pemetrexed. The brief summary says the study is comparing participants who receive sotorasib with chemotherapy versus pembrolizumab with chemotherapy.
This means the main research question is which treatment approach works better for the study group. The trial is not simply checking whether a single drug works in isolation; it is comparing treatment strategies in a real cancer setting.
Study phase and size
This is a Phase 3 trial, which usually means a larger study that compares treatments and looks for strong evidence of benefit. The planned enrollment is 721 participants.
A larger sample helps researchers compare results more reliably across the treatment groups. In this study, that size is important because the trial is measuring survival-related outcomes in a specific lung cancer population.
Outcomes being measured
The main outcome is progression-free survival (PFS). PFS is the time from randomization until the disease gets worse or the participant dies, whichever happens first.
Disease progression will be judged by an independent review using RECIST v1.1, which is a standard way to measure tumor response in cancer trials. The reviewers will not know which treatment the participant received, which helps reduce bias in reading the results.
The brief summary also says the study will compare overall survival (OS), which is the time until death from any cause. Together, PFS and OS help show whether one treatment strategy gives better control of the cancer and longer life.
What this means for patients
For patients, this trial is mainly about finding the better first treatment strategy for a very specific group of advanced lung cancer. The study looks at whether one treatment approach can delay cancer growth longer and improve survival.
Because the trial record includes Hydroxocobalamin among the intervention drugs, it is part of the research data for this study record. The source data do not give more detail about a separate Hydroxocobalamin-only trial, so the information here is limited to this lung cancer study record.